KRYS
Price
$142.76
Change
-$7.55 (-5.02%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
4.1B
48 days until earnings call
NTLA
Price
$9.73
Change
-$0.32 (-3.18%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
991.5M
37 days until earnings call
Ad is loading...

KRYS vs NTLA

Header iconKRYS vs NTLA Comparison
Open Charts KRYS vs NTLABanner chart's image
Krystal Biotech
Price$142.76
Change-$7.55 (-5.02%)
Volume$5.94K
Capitalization4.1B
Intellia Therapeutics
Price$9.73
Change-$0.32 (-3.18%)
Volume$109.44K
Capitalization991.5M
KRYS vs NTLA Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. NTLA commentary
Jan 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Hold and NTLA is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 15, 2025
Stock price -- (KRYS: $150.31 vs. NTLA: $10.05)
Brand notoriety: KRYS and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 120% vs. NTLA: 147%
Market capitalization -- KRYS: $4.32B vs. NTLA: $1.04B
KRYS [@Biotechnology] is valued at $4.32B. NTLA’s [@Biotechnology] market capitalization is $1.04B. The market cap for tickers in the [@Biotechnology] industry ranges from $385.53B to $0. The average market capitalization across the [@Biotechnology] industry is $2.41B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 5 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).

  • KRYS’s TA Score: 5 bullish, 5 bearish.
  • NTLA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а -3.53% price change this week, while NTLA (@Biotechnology) price change was -21.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.05%. For the same industry, the average monthly price growth was -1.49%, and the average quarterly price growth was -2.91%.

Reported Earning Dates

KRYS is expected to report earnings on May 12, 2025.

NTLA is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-7.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.1B) has a higher market cap than NTLA($991M). KRYS YTD gains are higher at: -4.053 vs. NTLA (-13.808). KRYS has higher annual earnings (EBITDA): 181M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. KRYS (588M). KRYS has less debt than NTLA: KRYS (7.48M) vs NTLA (102M). KRYS has higher revenues than NTLA: KRYS (242M) vs NTLA (43.1M).
KRYSNTLAKRYS / NTLA
Capitalization4.1B991M414%
EBITDA181M-527.52M-34%
Gain YTD-4.053-13.80829%
P/E Ratio80.13N/A-
Revenue242M43.1M561%
Total Cash588M658M89%
Total Debt7.48M102M7%
FUNDAMENTALS RATINGS
KRYS vs NTLA: Fundamental Ratings
KRYS
NTLA
OUTLOOK RATING
1..100
6959
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
27
Undervalued
PROFIT vs RISK RATING
1..100
21100
SMR RATING
1..100
8097
PRICE GROWTH RATING
1..100
6396
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (27) in the Biotechnology industry is somewhat better than the same rating for KRYS (81) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew somewhat faster than KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (21) in the Pharmaceuticals Major industry is significantly better than the same rating for NTLA (100) in the Biotechnology industry. This means that KRYS’s stock grew significantly faster than NTLA’s over the last 12 months.

KRYS's SMR Rating (80) in the Pharmaceuticals Major industry is in the same range as NTLA (97) in the Biotechnology industry. This means that KRYS’s stock grew similarly to NTLA’s over the last 12 months.

KRYS's Price Growth Rating (63) in the Pharmaceuticals Major industry is somewhat better than the same rating for NTLA (96) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than NTLA’s over the last 12 months.

KRYS's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as NTLA (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSNTLA
RSI
ODDS (%)
Bullish Trend 7 days ago
79%
Bullish Trend 7 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 7 days ago
74%
Bullish Trend 7 days ago
72%
Momentum
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 7 days ago
82%
MACD
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 7 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
77%
Bullish Trend 7 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
75%
Bearish Trend 7 days ago
89%
Advances
ODDS (%)
Bullish Trend 26 days ago
76%
Bullish Trend 13 days ago
78%
Declines
ODDS (%)
Bearish Trend 13 days ago
76%
Bearish Trend 7 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
76%
Aroon
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 7 days ago
90%
View a ticker or compare two or three
Ad is loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PSBJX24.280.21
+0.87%
Principal SmallCap J
IWEDX12.930.08
+0.62%
Voya Large Cap Value W
TIBOX25.710.04
+0.16%
Thornburg Investment Income Builder R6
FLRAX40.020.01
+0.02%
Nuveen Large Cap Select A
DISMX14.45-0.09
-0.62%
DFA International Small Cap Growth

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with CLDX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-1.71%
CLDX - KRYS
55%
Loosely correlated
-0.12%
BEAM - KRYS
47%
Loosely correlated
-3.22%
ZLDPF - KRYS
45%
Loosely correlated
-0.30%
BPMC - KRYS
45%
Loosely correlated
+18.22%
ALT - KRYS
44%
Loosely correlated
-1.31%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-1.47%
VCYT - NTLA
69%
Closely correlated
+2.99%
EDIT - NTLA
68%
Closely correlated
-7.94%
BEAM - NTLA
62%
Loosely correlated
-3.22%
CRSP - NTLA
61%
Loosely correlated
-2.12%
PRME - NTLA
57%
Loosely correlated
-5.78%
More